Disclosed are azaindazole compounds of Formula (I): or a pharmaceutically acceptable salt thereof, wherein: X is O and Y is N; or X is S and Y is CH; Z is CR2 or N; Q is a heteroaryl; and R1 is defined herein. Also disclosed are methods of using such compounds in the treatment of at least one CYP17 associated condition, such as, for example, cancer, and pharmaceutical compositions comprising such compounds.
披露了公式(I)的氮杂
吲唑化合物:或其药用可接受盐,其中:X是O且Y是N;或者X是S且Y是CH;Z是CR2或N;Q是杂芳基;R1如本文所定义。还披露了使用这些化合物治疗至少一种与CYP17相关的病症的方法,例如,癌症,以及包含这些化合物的药物组合物。